NDC Pharmacologic Class N0000175078 CD20-directed Antibody Interactions [MoA]

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Product Type
0078-0669Arzerra OfatumumabInjection, SolutionIntravenousNovartis Pharmaceuticals CorporationHuman Prescription Drug
0078-0690Arzerra OfatumumabInjection, SolutionIntravenousNovartis Pharmaceuticals CorporationHuman Prescription Drug
50242-051Rituxan RituximabInjection, SolutionIntravenousGenentech, Inc.Human Prescription Drug
50242-053Rituxan RituximabInjection, SolutionIntravenousGenentech, Inc.Human Prescription Drug
50242-070Gazyva ObinutuzumabInjection, Solution, ConcentrateIntravenousGenentech, Inc.Human Prescription Drug
50242-108Rituxan Hycela Rituximab And HyaluronidaseInjection, SolutionSubcutaneousGenentech, Inc.Human Prescription Drug
50242-109Rituxan Hycela Rituximab And HyaluronidaseInjection, SolutionSubcutaneousGenentech, Inc.Human Prescription Drug
50242-150Ocrevus OcrelizumabInjectionIntravenousGenentech, Inc.Human Prescription Drug

There are 8 NDC products with the pharmacologic class CD20-directed Antibody Interactions [MoA].